- Open Access
Transformation of MCF-10A cells by random mutagenesis with frameshift mutagen ICR191: A model for identifying candidate breast-tumor suppressors
© Zientek-Targosz et al; licensee BioMed Central Ltd. 2008
- Received: 03 April 2008
- Accepted: 05 June 2008
- Published: 05 June 2008
Widely accepted somatic mutation theory of carcinogenesis states that mutations in oncogenes and tumor suppressor genes in genomes of somatic cells is the cause of neoplastic transformation. Identifying frequent mutations in cancer cells suggests the involvement of mutant genes in carcinogenesis.
To develop an in vitro model for the analysis of genetic alterations associated with breast carcinogenesis, we used random mutagenesis and selection of human non-tumorigenic immortalized breast epithelial cells MCF-10A in tissue-culture conditions that mimic tumor environment. Random mutations were generated in MCF-10A cells by cultivating them in a tissue-culture medium containing the frameshift-inducing agent ICR191. The first selective condition we used to transform MCF1-10A cells was cultivation in a medium containing mutagen at a concentration that allowed cell replication despite p53 protein accumulation induced by mutagen treatment. The second step of selection was either cell cultivation in a medium with reduced growth-factor supply or in a medium that mimics a hypoxia condition or growing in soft agar. Using mutagenesis and selection, we have generated several independently derived cultures with various degrees of transformation. Gene Identification by Nonsense-mediated mRNA decay Inhibition (GINI) analysis has identified the ICR191-induced frameshift mutations in the TP53, smoothelin, Ras association (RalGDS/AF-6) domain family 6 (RASSF6) and other genes in the transformed MCF-10A cells. The TP53 gene mutations resulting in the loss of protein expression had been found in all independently transformed MCF-10A cultures, which form large progressively growing tumors with sustained angiogenesis in nude mice.
Identifying genes containing bi-allelic ICR191-induced frameshift mutations in the transformed MCF-10A cells generated by random mutagenesis and selection indicates putative breast-tumor suppressors. This can provide a model for studying the role of mutant genes in breast carcinogenesis.
- Soft Agar
- Array Comparative Genomic Hybridization
- TP53 Gene
- Random Mutagenesis
It has been proposed that, even from its earliest stages, cancer development is associated with DNA replication stress, which leads to genomic instability and selective pressure for p53 inactivation . This hypothesis was based on the fact of frequent inactivation of the p53 pathway in human tumors and on a demonstration that human early pre-cancerous lesions show signs of DNA damage-response activation [1–4]. These observations suggest that selection for cells that can tolerate DNA damage-signaling in precancerous cells is likely to take place during the early stages of tumor progression in vivo. We hypothesized that an extended in vitro cultivation of human immortalized cells in tissue culture conditions that generate DNA damage response activation and create selective pressure for p53 inactivation can result in tumorigenic cell transformation.
MCF-10A cells are frequently used as a normal control in breast cancer studies [5–9]. These cells were derived from the mammary tissue of a cystic fibrosis patient and have normal mammary epithelial cell morphology. These cells do not have mutations in the p53 gene but show homozygous loss of the p16/p15 locus and do not form tumors in nude mice or colonies in semi-solid low melting agarose. Similar to normal human breast epithelial cells, at confluence the MCF-10A cells form dome structures in tissue culture plates and produce mammary spheres in 3D collagen culture. All of these characteristics make MCF-10A cells a model of choice for breast tumor progression studies.
The role of genomic instability in carcinogenesis is thought to generate variability within the tumor cell population and to facilitate selection of genetic variants that have growth advantages in the tumor environment. We speculated that continuous chronic exposure of cells to mutagens at concentrations that induce activation of the DNA damage-response, although still allowing DNA replication and cell proliferation, would provide conditions for both, mimicking genomic instability through the increased rate of mutations and selecting genetic variants that acquire tolerance to DNA damage-response activation. To mimic genomic instability and generate genetic variability within populations of MCF-10A cells, we used the acridine mutagen ICR191. This DNA-intercalating chemical produces an insertion of one G:C base-pair in a short poly-G:C repetitive DNA sequence. We rationalized that frameshift mutations produced by ICR191 treatment may cause the inactivation of tumor-suppressor genes related to breast carcinogenesis and result in the transformation of MCF-10A cells. Frameshift mutations, which generate premature translation-termination codons (TPC) located more than 25 base pairs upstream of the last exon/exon junction, frequently initiate mutant-mRNA degradation through the nonsense-mediated mRNA decay (NMD) mechanism[12, 13]. Thus, the mutant gene can be identified in the transformed cells using GINI analysis, as we have shown in prostate and colon cancer cell lines [15, 16]. Bi-allelic inactivation of a gene in the transformed MCF10-A cultures may indicate a potential tumor-suppressor gene related to breast carcinogenesis.
Transformation of MCF-10A cells using ICR191 treatment
After six months of selection for the resistance to DNA damage-signaling, all five cultures had a higher than control untreated cells rate of replication in the presence of mutagen (not shown). Also, all five cultures had acquired signs of cell transformation, such as the loss of contact inhibition at high density and the ability to form growing colonies in soft agar (Figures 2A and 2B). One culture (MCF10Aε) has acquired a higher rate of cell proliferation in the absence of mutagen (Figure 2C). Following subcutaneous injections of 5 million cells into the flanks of nude mice, three out of five cultures (MCF10Aα, MCF10Aγ and MCF10Aδ) produced small (~2 mm in diameter) palpable tumors. These tumors were localized at the site of inoculation for more than four months without an increase in size.
The second step of selection used to isolate more aggressive variants of the MCF-10A cells involved selection for either the ability of anchorage-independent growth or the ability to grow in a medium with either reduced growth-factor supply or resistance to hypoxia. Selection for anchorage-independent growth was applied to the MCF10Aα and MCF10Aβ cultures. Cells from these cultures had been cloned in soft agar and, after two weeks, four of the fastest-growing colonies of MCF10Aα cells, and one colony of MCF10Aβ cells, were isolated and expanded in culture. After subcutaneous injections of 5 million of these cells into the flanks of nude mice, the soft agar-derived clone of MCF10Aβ cells (MCF10Aβ1) produced a large (~1 cm in diameter), progressively growing tumor four months after inoculation. Two soft agar-derived clones from the MCF10α culture, MCF10α3 and MCF10α4, produced large and small tumors, respectively.
Individual cell-lines were established from both large and small tumors and expanded in culture. The names of cell-lines derived from large and small tumors are subsequently denoted with the letters L and S, respectively. Inoculations of cell-lines derived from large tumors resulted in the formation of large tumors (1 cm in diameter) in five out of five mice after one month. In contrast, inoculations of cell-lines derived from the small tumors produced either small tumors or none at all.
Spectral Karyotyping (SKY) and array comparative genomic hybridization of transformed cells shows minimal chromosomal instability
GINI analysis identifies ICR191-induced mutations in the transformed MCF-10A cells
The TP53 gene is known to be frequently mutated in more than half of all human cancers, including breast cancer. Since the TP53 gene is the main regulator of DNA damage-response and the transformed derivatives of MCF-10A cells had been selected for the ability to replicate despite DNA damage-response activation, we analyzed all the transformed MCF-10A cultures for the mutations in the p53 gene. We found that all MCF-10A cultures that can produce large, continuously growing tumors in nude mice contained p53 gene mutations. The MCF10AγL culture had two heterozygous mutations that were different from those in the MCF10β1 cells (Figure 5A), and the MCF10AαL culture had one heterozygous mutation that was identical to one mutation found in the MCF10 β1 cells. Although the mutation had been identified only in one allele, the MCF10AαL cells, similarly to the MCF10AγL and MCF10β1, do not express p53 protein (Figure 5B). The DNA sequencing analysis of the p53 gene in MCF10Aα3 and MCF10Aα4 cells generated from soft agar growing clones has identified the mutation identical to that in MCF10AαL cells. Western blot analysis has shown that MCF10Aα3 cells, which can produce large tumors after inoculations into nude mice, do not express p53 protein, while the MCF10Aα4, which cannot produce large tumors, do. Similarly, MCF10Aδ and MCF10Aε cultures, which, after all rounds of selection, could form only small tumors in nude mice, had a wild-type allele of the p53 gene and showed p53 protein-accumulation in response to treatment with ICR191 (Figure 5B). On the other hand, the MCF10AγS cells, which do not express p53 protein due to mutations identical to that in MCF10AγL cells, did not produce large tumors in nude mice, suggesting that p53 inactivation was necessary but not sufficient for in vivo tumor growth.
In contrast to the p53 gene mutations, the mutation in the SMTN gene had been found only in the MCF10Aβ1 cells. All other transformed MCF-10A cultures, including the related MCF10AβL cell-line derived from a large tumor produced by MCF10Aβ cells selected for resistance to hypoxia, contained wild-type alleles of this gene. To identify other genes mutated in the process of in vitro transformation, we analyzed, using GINI, the MCF10Aα4 and MCF10αL cultures. Sequencing of selected candidate genes has identified heterozygous frameshift mutations in the Ras association (RalGDS/AF-6) domain family 6 (RASSF6) (Figure 5C) in the MCF10Aα4 cells and in the kinesin family member 22 (KIF22) in the MCF10αL cells.
It has been hypothesized that the selection of genetic or epigenetic DNA alterations, which provide growth/survival advantages to somatic cells in the context of the tumor environment, is the driving force for tumor progression. We have demonstrated that the simulation of Darwinian evolution in vitro by generating random mutations and selecting in tissue-culture conditions that mimic the tumor environment can result in the tumorigenic transformation of non-tumorigenic cells. Due to the stochastic nature of mutations, all the transformed cultures of the MCF-10A cells had various degrees of tumorigenicity. Only three out of five cultures, which had been subjected to random mutagenesis and selection, have acquired the ability to form large, continuously growing tumors with sustained angiogenesis in nude mice, despite the fact that all five cultures were treated identically. All three cultures had gained inactivating mutations in the TP53 gene, resulting in the loss of protein expression. TP53 gene mutations identified in the transformed MCF10AαL, MCF10AβL and MCF10AγL cells derived from tumors growing in nude mice were identical to the mutations identified in the corresponding cultures derived after in vitro selection either for resistance to hypoxia or to reduced growth-factor supply, or after selection for growth in soft agar. This result suggests that in each transformed culture TP53-inactivating mutations had occurred during the first round of selection when cells were cultivated in the presence of ICR191, and that the progenitors of rare cells that had acquired TP53 gene mutations underwent clonal expansion during the second round of selection in tissue-culture conditions that simulated tumor environment.
ICR191-induced frameshift mutations generate premature translation termination codons (PTC), which frequently initiate mutant mRNA degradations via a nonsense-mediated mRNA decay (NMD) pathway. Genes mutated in the cells transformed by ICR191 exposure can be identified using microarray-based analysis of mRNA levels alterations induced by the inhibition of NMD in the transformed as well as in the non-transformed control cells. Identifying genes in the transformed cells containing either inactivating mutations in both alleles or a mutation in one allele accompanied by the loss of the second allele can indicate potential tumor suppressors. Bi-allelic mutations of the TP53 gene identified in the transformed MCF10Aβ1 cells using NMD inhibition demonstrate the proof-of-principle that our model of cell-transformation by ICR191 exposure can be used for the identification of breast tumor suppressors.
The RASS6 gene was the other known tumor-suppressor gene that has been identified using NMD-inhibition to contain frameshift mutation in the clone of transformed MCF-10A cells derived from a colony growing in soft agar. The expression of this gene has been shown to be down-regulated in 30–60% of tumor-derived tissues from the breast, colon, kidney, liver, rectum, pancreas, stomach and thyroid gland compared to normal tissue . Due to mono-allelic occurrence in the transformed MCF-10A cells, the mutation in the RASS6 gene, as well as the heterozygous mutations in USP10 and KIF22 genes, can be passenger mutations not relevant to cell transformation. We cannot rule out the possibility, however, that haploinsufficiency caused by RASSF6 heterozygous mutation could contribute to the survival of the MCF10Aα4 clone in soft agar.
Smoothelin was the gene identified by NMD-inhibition to contain homozygous ICR191-induced mutation in the MCF10Aβ1 cells. The protein encoded by this gene associates with stress fibers and constitutes part of the cytoskeleton. Since the SMTN gene mutation has been identified in a clone of MCF10Aβ cells selected for the ability to grow in soft agar, inactivation of this gene could promote anchorage-independent growth, a property of tumor cells allowing them to grow in improper locations in vivo, a characteristic that distinguishes malignant from benign tumors. Interestingly, SMTN gene mutations have recently been identified in colorectal tumors, and the gene has been suggested as a candidate colorectal cancer gene. We are planning to use MCF10Aβ1 cells, which are null for the SMTN gene expression, as a model to study the possible role of the gene in breast carcinogenesis.
We have demonstrated that by using NMD-inhibition and microarray-based gene expression analysis we can identify mutant genes in tumorigenic cells transformed by random mutagenesis and selection. This strategy can be applied to the identification of genes and pathways controlling particular traits of cell transformation. For example, similar to identifying TPP53 gene mutations after selecting for tolerance to DNA damage-response activation, GINI analysis of clones isolated after random mutagenesis and selection of cells for resistance to chemotherapeutic drugs can result in the identification of other genes controlling response to chemotherapy. Also, our model of random mutagenesis and selection can be used for microarray-based monitoring of gene-expression alterations accompanying progression from almost normal to a transformed phenotype of breast epithelial cells.
Cell-culture media and chemicals
The immortalized, non-transformed human mammary epithelial cell-line, MCF-10A, was grown on standard tissue-culture plastic in a 5% CO2-humidified incubator at 37°C in Complete MCF-10A Growth Medium composed of DMEM/F12 (Mediatech, Inc., Herndon, VA) supplemented with 5% donor horse serum, 20 ng/ml epidermal growth factor (EGF), 10 μg/ml insulin, 0.5 μg/ml hydrocortisone (Sigma, St. Louis, MO), 100 ng/ml cholera toxin (Cambrex, Westborough, MA), and 100 units/ml penicillin and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA). A Growth Factor-Reduced MCF-10A Medium for the second step of transformation and culturing transformed clones was composed of DMEM/F12 supplemented with 5% donor horse serum (Sigma, St. Louis, MO) and 100 units/ml penicillin and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA), without the addition of supplements.
The acridine mutagen ICR191 (Sigma Chemical Co., St. Louis, MO) was dissolved at 1 mg/mL in 0.01 M HCl and was used as a stock solution before diluting in the tissue-culture medium at 500 ng/ml concentration.
Transformation of MCF-10A cells using random mutagenesis and selection
Two steps of mutagenesis and selection had been used to achieve the transformation of MCF-10A cells. The first step of selection was for the ability to replicate despite DNA damage-response activation. In this step, 1 million MCF-10A cells were seeded in a 100 mm tissue-culture plate and cultivated for six months in Complete MCF-10A Growth Medium containing 500 ng/ml of ICR191. During this process, as cells reached confluence, they were trypsinized, and half the cells were frozen in liquid nitrogen. The remaining cells were returned to the culture. In the second step, cells were selected either for the ability to grow in the medium with reduced growth-factor supply, for the ability to grow in the hypoxic condition, or for anchorage-independent growth. To select cells resistant to a reduced growth-factor supply, cells were cultivated in the Growth Factor-Reduced MCF-10A Medium containing 500 ng/ml of ICR191 for one to three months. To select cells resistant to hypoxia, cells were cultivated in the Complete MCF-10A Growth Medium containing 100 μM of cobalt chloride, which is known to generate hypoxic environment , and 500 ng/ml of ICR191 for one month. To select for the ability for anchorage-independent growth, cells were challenged to grow in soft agar.
1 × 105 cells in Complete MCF-10A Growth Medium were seeded into six-well plates with 2 ml 0.33% (w/v) low-melting agarose, which was overlaid onto 2 ml of 0.6% (w/v) agarose and fed every other day by exchanging 1.5 ml medium on top of the soft agar. Soft-agar cultures were maintained at 37°C and observed microscopically for the appearance of colonies. After three to four weeks in culture, the colonies were counted. In cases where cultures were to be established from anchorage-independent colonies, the top layer of low-melting agarose was plated into tissue-culture dishes and kept in Complete MCF-10A Growth Medium. Clones were picked using cloning cylinders and developed into cell-lines.
Nude mice tumorigenicity assay
Cells in phosphate-buffered saline were mixed 1:1 with Matrigel basement membrane matrix (BD Biosciences, Franklin Lakes, NJ) and 3–4 × 106 cells in 100–150 μl were injected subcutaneously into the flanks of 5-week-old athymic female Ncr -nu/nu mice (National Cancer Institute). The animals were maintained in accordance with institutional guidelines at the Laboratory Animal Facility at RPCI for six to eight months and palpated weekly for tumor appearance. When tumor nodules reached 1–2 cm in size, the mice were euthanized by exposure to carbon dioxide. The tumors were excised and divided into three pieces for developing into cell-lines to be frozen for future microarray analysis, fixed in neutral buffered formalin and embedded in paraffin for a routine histological evaluation with 5 μm hematoxylin and eosin (H&E) stained sections. Histological procedures were performed at the RPCI Pathology Core Facility.
Identifying mutant genes in the transformed MCF-10A cells using inhibition of nonsense-mediated decay and Affymetrix oligonucletide U133Plus2.0 GeneChip analysis was performed as described previously for prostate cells . Briefly, control untransformed MCF-10A cells and the MCF-10A transformed derivative cells were grown in Complete MCF-10A Growth Medium until they reached 70–80% of confluency. To inhibit NMD in cells, emetine (100 μg/ml) was added to the tissue-culture medium and, eight hours later, the total RNA was prepared with TRIZOL reagents (Invitrogen, Carlsbad, CA) according to manufacturer's specifications from emetine-treated as well as untreated cells. The integrity and purity of the total RNA were analyzed using a microfluidic electrophoretic system (Agilent 2100 Bioanalyzer; Agilent Technologies). RNA samples were processed and then hybridized to Human Genome U133APlus2.0 GeneChip (Affymetrix Inc, Santa Clara, CA), according to the manufacturer's instructions, by the Gene Expression Core facility at Roswell Park Cancer Institute. GeneChip expression array analysis was performed using Affymetrix Microarray Suite software, version 5 (GeneChip Analysis Suite). This software uses two independent sets of algorithms, a quantitative algorithm (robust estimator of the mean difference in probe intensities) that computes the raw signal and the SLR directly from the hybridization intensities of the probes, as well as a confidence algorithm (non-parametric) that provides P-values to estimate the confidence in detection (absent or present) or change (increase, decrease or no change) of a specific target.
To select candidate genes out of hundreds genes that show mRNA increase following emetine treatment in the transformed cells for sequencing analysis, we used the following cut-off criteria:1) the level of expression of a gene in the emetine-untreated transformed cells had to be more than threefold lower than that in emetine-untreated control MCF-10A cells; 2) the gene expression in control untreated MCF-10A cells had to be detected as present; 3) fold-change increase of mRNA level following emetine treatment in the transformed cells had to be at least threefold higher than that in the untransformed control cells.
One microgram of total RNA from emetine-treated transformed MCF-10A cells was reverse transcribed using the SuperScript II protocol (Invitrogen, Carlsbad, CA). Overlapping PCR primer sets were used to generate products spanning entire open-reading frames for candidate genes. Primers for sequencing analysis were designed using Primer3 software available online . To sequence the p53 gene from genomic DNA, the sequences of p53 gene exons with the flanking introns were retrieved from the genomic databases, and the primers for PCR amplification of genomic DNA fragments of p53 gene were designed using Primer3 software. These are available upon request. The PCR products were gel-purified and sequenced using Applied Biosystems' PRISM 3100 Genetic Analyzer at the DNA Sequencing section of the Biopolymer Facility at RPCI.
TP53 western blot analysis
Whole-cell extracts were prepared in a RIPA buffer, and protein samples were denatured, separated by SDS/PAGE gel, and transferred onto a Hybond-P nitrocellulose membrane (Amersham Pharmacia) by using the MiniPROTEAN 3 apparatus (Bio-Rad). Membranes were rinsed and blocked with 0.05% Tween 20 (Sigma) and 1% skimmed milk in PBS for one hour with three changes of this blocking buffer every 20 minutes at room temperature. Membranes were then incubated with DO1 antibody conjugated with horseredish peroxidase (Santa Cruz Biotechnology, Santa Cruz) in a blocking buffer. After washing the membranes in blocking buffer for one hour with a change of the buffer every 15 minutes at room temperature, membranes were visualized using ECL plus the Western blotting detection system (Amersham Pharmacia). The anti-actin monoclonal antibody (Sigma) was hybridized to membranes to serve as a measure of loading control.
Flow cytometry analysis
After rinsing with a phosphate-buffered saline solution, the cells were trypsinized from culture dishes, rinsed with PBS, fixed in 70% ice-cold ethanol, and stained with 10 μg/ml propidium iodide (PI) for 30 minutes. Flow cytometry analysis was performed on the Coulter FACS analyzer equipped with an air-cooled argon laser, producing 488 nm light in which fluorescence light-emission is collected with a 620BP filter. An extended analysis of the DNA content and calculations of the percentage of cells in each phase of the cell-cycle were performed on ModFit Lt software (Verity Software House, Topsham, ME).
Cell cultures usually received treatments with Colcemid (0.03–0.06 μg/ml). However, nocodazole (0.5 μg/ml) was found to give the best results with some cells. Chromosome spreads were prepared using air-drying methods. After sequential digestion with RNase and pepsin according to the procedure recommended by Applied Spectral Imaging, Inc. (ASI: Vista, CA 92081), the chromosomal DNA on the slides was denatured in 70% formamide and then hybridized with a cocktail of human SKY paint probes tagged with various nucleotide analogues (i.e., a mixture of individual chromosome DNA prepared by flow-sorting and PCR amplification). Thirty to 50 mitoses were chosen at random, and the images developed by combinations of five different flouorophores, such as Rhodamine, Texas-Red, Cy5, FITC and Cy5.5, were captured with a Spectral cube and Interferometer module installed on a Nikon microscope. Spectra-Karyotypes were carried out using SKY View software (Version 1.62).
Array comparative genomic hybridization analysis
The preparation of Roswell Park Cancer Institute (RPCI) custom CGH arrays using RPCI-11 BACs has been described previously[25, 26]. Briefly, the RPCI array contains ~6,000 RPCI-11 BAC clones that provide an average resolution across the genome of 420 kilobases. BACs were printed in duplicate on amino-silanated glass slides (Schott Nexterion, type A) using a MicroGrid ll TAS arrayer (Apogent Discoveries, Hudson, NH) to generate an array of ~12,000 elements. Genomic control MCF-10A DNA and the transformed MCF10AαL DNA were fluorescently labeled by random priming and hybridized, as described . The hybridized slides were scanned using a Genepix 4200A scanner (Axon, Inc., Union City, CA) to generate high-resolution (10 μm) images for both Cy3 and Cy5 channels, and image analysis was performed using ImaGene (version 4.1) software (BioDiscovery, Inc., El Segundo, CA).
This work was supported by NIH CA109256 and by Department of Defense BC 032564 grants. We thank Dr. John Cowell for critical reading of the manuscript.
- Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Kastrinakis NG, Levy B: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005, 434 (7035): 907-913. 10.1038/nature03485View ArticlePubMedGoogle Scholar
- Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005, 434 (7035): 864-870. 10.1038/nature03482View ArticlePubMedGoogle Scholar
- Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A: Inactivation of the p53 pathway in retinoblastoma. Nature. 2006, 444 (7115): 61-66. 10.1038/nature05194View ArticlePubMedGoogle Scholar
- Toledo F, Wahl GM: Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006, 6: 909-923. 10.1038/nrc2012View ArticlePubMedGoogle Scholar
- Golubovskaya VM, Virnig C, Cance WG: TAE226-Induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog. 2007.Google Scholar
- Spink BC, Cole RW, Katz BH, Gierthy JF, Bradley LM, Spink DC: Inhibition of MCF-7 breast cancer cell proliferation by MCF-10A breast epithelial cells in coculture. Cell Biol Int. 2006, 30 (3): 227-238. 10.1016/j.cellbi.2005.11.006View ArticlePubMedGoogle Scholar
- Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun. 2005, 337 (1): 224-231. 10.1016/j.bbrc.2005.09.040View ArticlePubMedGoogle Scholar
- Shun MC, Yu W, Gapor A, Parsons R, Atkinson J, Sanders BG, Kline K: Pro-apoptotic mechanisms of action of a novel vitamin E analog (alpha-TEA) and a naturally occurring form of vitamin E (delta-tocotrienol) in MDA-MB-435 human breast cancer cells. Nutr Cancer. 2004, 48 (1): 95-105. 10.1207/s15327914nc4801_13View ArticlePubMedGoogle Scholar
- Ciftci K, Su J, Trovitch PB: Growth factors and chemotherapeutic modulation of breast cancer cells. J Pharm Pharmacol. 2003, 55 (8): 1135-1141. 10.1211/002235703322277177View ArticlePubMedGoogle Scholar
- Cowell JK, LaDuca J, Rossi MR, Burkhardt T, Nowak NJ, Matsui S: Molecular characterization of the t(3;9) associated with immortalization in the MCF10A cell line. Cancer Genet Cytogenet. 2005, 163 (1): 23-29. 10.1016/j.cancergencyto.2005.04.019View ArticlePubMedGoogle Scholar
- Chen WD, Eshleman JR, Aminoshariae MR, Ma AH, Veloso N, Markowitz SD, Sedwick WD, Veigl ML: Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells. J Natl Cancer Inst. 2000, 92 (6): 480-485. 10.1093/jnci/92.6.480View ArticlePubMedGoogle Scholar
- Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE: Nonsense-mediated decay approaches the clinic. Nat Genet. 2004, 36 (8): 801-808. 10.1038/ng1403View ArticlePubMedGoogle Scholar
- Maquat LE: Nonsense-mediated mRNA decay in mammals. J Cell Sci. 2005, 118 (Pt 9): 1773-1776. 10.1242/jcs.01701View ArticlePubMedGoogle Scholar
- Noensie EN, Dietz HC: A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat Biotechnol. 2001, 19 (5): 434-439. 10.1038/88099View ArticlePubMedGoogle Scholar
- Ionov Y, Nowak N, Perucho M, Markowitz S, Cowell JK: Manipulation of nonsense mediated decay identifies gene mutations in colon cancer Cells with microsatellite instability. Oncogene. 2004, 23 (3): 639-645. 10.1038/sj.onc.1207178View ArticlePubMedGoogle Scholar
- Rossi MR, Hawthorn L, Platt J, Burkhardt T, Cowell JK, Ionov Y: Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis. Cancer Genet Cytogenet. 2005, 161 (2): 97-103. 10.1016/j.cancergencyto.2005.02.006View ArticlePubMedGoogle Scholar
- Brenner AJ, Aldaz CM: Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res. 1995, 55 (13): 2892-2895.PubMedGoogle Scholar
- Helton ES, Chen X: p53 modulation of the DNA damage response. J Cell Biochem. 2007, 100 (4): 883-896. 10.1002/jcb.21091View ArticlePubMedGoogle Scholar
- Allen NP, Donninger H, Vos MD, Eckfeld K, Hesson L, Gordon L, Birrer MJ, Latif F, Clark GJ: RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene. 2007, 26 (42): 6203-6211. 10.1038/sj.onc.1210440View ArticlePubMedGoogle Scholar
- Schwartz MA: Integrins, oncogenes, and anchorage independence. J Cell Biol. 1997, 139 (3): 575-578. 10.1083/jcb.139.3.575PubMed CentralView ArticlePubMedGoogle Scholar
- Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J: The genomic landscapes of human breast and colorectal cancers. Science. 2007, 318 (5853): 1108-1113. 10.1126/science.1145720View ArticlePubMedGoogle Scholar
- Salnikow K, Su W, Blagosklonny MV, Costa M: Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen species-independent mechanism. Cancer Res. 2000, 60 (13): 3375-3378.PubMedGoogle Scholar
- Karpf AR, Matsui S: Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res. 2005, 65 (19): 8635-8639. 10.1158/0008-5472.CAN-05-1961View ArticlePubMedGoogle Scholar
- Cowell JK, Nowak NJ: High-resolution analysis of genetic events in cancer cells using bacterial artificial chromosome arrays and comparative genome hybridization. Adv Cancer Res. 2003, 90: 91-125.View ArticlePubMedGoogle Scholar
- Cowell JK, Matsui S, Wang YD, LaDuca J, Conroy J, McQuaid D, Nowak NJ: Application of bacterial artificial chromosome array-based comparative genomic hybridization and spectral karyotyping to the analysis of glioblastoma multiforme. Cancer Genet Cytogenet. 2004, 151 (1): 36-51. 10.1016/j.cancergencyto.2003.09.012View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.